Trial Outcomes & Findings for A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations. (NCT NCT04903093)

Results Overview

Area under the plasma concentration time profile from time 0 extrapolated to infinity (AUCinf) was measured. The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

19 participants

Primary outcome timeframe

0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.

Results posted on

2024-11-14

Participant Flow

Part A was a crossover, 3-treatment, 6-sequence, 3-periods design. With completion of Part A of the study, participants entered Part B, which included 6 periods with 6 sequences. Thus, participants who completed Part A and then Part B were combined. Enrolled participants, including 18 participants who completed both Parts A and B and 1 participant who withdrew by the participant, are presented in the Participant Flow.

Participant milestones

Participant milestones
Measure	Treatment A-> B-> C-> D-> E-> F-> G-> H-> I Part A of the study included administration of treatments A - C. A=a single dose of abrocitinib 200 mg commercial tablet; B=a single dose of abrocitinib 200 mg oral suspension formulation 1, C=famotidine (40 mg) administered 120 minutes before a single dose of 200 mg abrocitinib commercial tablet. Part B of the study included administration of treatments D - I, famotidine 40 mg tablet + abrocitinib 200 mg oral suspension formulation X (X=1-6), and treatments B, J - N, abrocitinib 200 mg oral suspension formulation X (X=1-6) only. All were under fasted state on Day 1 of each period.	Treatment A-> C-> B-> L-> M-> N-> B-> J-> K Part A of the study included administration of treatments A - C. A=a single dose of abrocitinib 200 mg commercial tablet; B=a single dose of abrocitinib 200 mg oral suspension formulation 1, C=famotidine (40 mg) administered 120 minutes before a single dose of 200 mg abrocitinib commercial tablet. Part B of the study included administration of treatments D - I, famotidine 40 mg tablet + abrocitinib 200 mg oral suspension formulation X (X=1-6), and treatments B, J - N, abrocitinib 200 mg oral suspension formulation X (X=1-6) only. All were under fasted state on Day 1 of each period.	Treatment B-> A-> C-> K-> L-> M-> N-> B-> J Part A of the study included administration of treatments A - C. A=a single dose of abrocitinib 200 mg commercial tablet; B=a single dose of abrocitinib 200 mg oral suspension formulation 1, C=famotidine (40 mg) administered 120 minutes before a single dose of 200 mg abrocitinib commercial tablet. Part B of the study included administration of treatments D - I, famotidine 40 mg tablet + abrocitinib 200 mg oral suspension formulation X (X=1-6), and treatments B, J - N, abrocitinib 200 mg oral suspension formulation X (X=1-6) only. All were under fasted state on Day 1 of each period.	Treatment B-> C-> A-> I-> D-> E-> F-> G-> H Part A of the study included administration of treatments A - C. A=a single dose of abrocitinib 200 mg commercial tablet; B=a single dose of abrocitinib 200 mg oral suspension formulation 1, C=famotidine (40 mg) administered 120 minutes before a single dose of 200 mg abrocitinib commercial tablet. Part B of the study included administration of treatments D - I, famotidine 40 mg tablet + abrocitinib 200 mg oral suspension formulation X (X=1-6), and treatments B, J - N, abrocitinib 200 mg oral suspension formulation X (X=1-6) only. All were under fasted state on Day 1 of each period.	Treatment C-> A-> B-> H-> I-> D-> E-> F-> G Part A of the study included administration of treatments A - C. A=a single dose of abrocitinib 200 mg commercial tablet; B=a single dose of abrocitinib 200 mg oral suspension formulation 1, C=famotidine (40 mg) administered 120 minutes before a single dose of 200 mg abrocitinib commercial tablet. Part B of the study included administration of treatments D - I, famotidine 40 mg tablet + abrocitinib 200 mg oral suspension formulation X (X=1-6), and treatments B, J - N, abrocitinib 200 mg oral suspension formulation X (X=1-6) only. All were under fasted state on Day 1 of each period.	Treatment C-> B-> A-> J-> K-> L-> M-> N-> B Part A of the study included administration of treatments A - C. A=a single dose of abrocitinib 200 mg commercial tablet; B=a single dose of abrocitinib 200 mg oral suspension formulation 1, C=famotidine (40 mg) administered 120 minutes before a single dose of 200 mg abrocitinib commercial tablet. Part B of the study included administration of treatments D - I, famotidine 40 mg tablet + abrocitinib 200 mg oral suspension formulation X (X=1-6), and treatments B, J - N, abrocitinib 200 mg oral suspension formulation X (X=1-6) only. All were under fasted state on Day 1 of each period.
Overall Study STARTED	3	3	3	4	3	3
Overall Study COMPLETED	3	3	3	3	3	3
Overall Study NOT COMPLETED	0	0	0	1	0	0

Reasons for withdrawal

Reasons for withdrawal
Measure	Treatment A-> B-> C-> D-> E-> F-> G-> H-> I Part A of the study included administration of treatments A - C. A=a single dose of abrocitinib 200 mg commercial tablet; B=a single dose of abrocitinib 200 mg oral suspension formulation 1, C=famotidine (40 mg) administered 120 minutes before a single dose of 200 mg abrocitinib commercial tablet. Part B of the study included administration of treatments D - I, famotidine 40 mg tablet + abrocitinib 200 mg oral suspension formulation X (X=1-6), and treatments B, J - N, abrocitinib 200 mg oral suspension formulation X (X=1-6) only. All were under fasted state on Day 1 of each period.	Treatment A-> C-> B-> L-> M-> N-> B-> J-> K Part A of the study included administration of treatments A - C. A=a single dose of abrocitinib 200 mg commercial tablet; B=a single dose of abrocitinib 200 mg oral suspension formulation 1, C=famotidine (40 mg) administered 120 minutes before a single dose of 200 mg abrocitinib commercial tablet. Part B of the study included administration of treatments D - I, famotidine 40 mg tablet + abrocitinib 200 mg oral suspension formulation X (X=1-6), and treatments B, J - N, abrocitinib 200 mg oral suspension formulation X (X=1-6) only. All were under fasted state on Day 1 of each period.	Treatment B-> A-> C-> K-> L-> M-> N-> B-> J Part A of the study included administration of treatments A - C. A=a single dose of abrocitinib 200 mg commercial tablet; B=a single dose of abrocitinib 200 mg oral suspension formulation 1, C=famotidine (40 mg) administered 120 minutes before a single dose of 200 mg abrocitinib commercial tablet. Part B of the study included administration of treatments D - I, famotidine 40 mg tablet + abrocitinib 200 mg oral suspension formulation X (X=1-6), and treatments B, J - N, abrocitinib 200 mg oral suspension formulation X (X=1-6) only. All were under fasted state on Day 1 of each period.	Treatment B-> C-> A-> I-> D-> E-> F-> G-> H Part A of the study included administration of treatments A - C. A=a single dose of abrocitinib 200 mg commercial tablet; B=a single dose of abrocitinib 200 mg oral suspension formulation 1, C=famotidine (40 mg) administered 120 minutes before a single dose of 200 mg abrocitinib commercial tablet. Part B of the study included administration of treatments D - I, famotidine 40 mg tablet + abrocitinib 200 mg oral suspension formulation X (X=1-6), and treatments B, J - N, abrocitinib 200 mg oral suspension formulation X (X=1-6) only. All were under fasted state on Day 1 of each period.	Treatment C-> A-> B-> H-> I-> D-> E-> F-> G Part A of the study included administration of treatments A - C. A=a single dose of abrocitinib 200 mg commercial tablet; B=a single dose of abrocitinib 200 mg oral suspension formulation 1, C=famotidine (40 mg) administered 120 minutes before a single dose of 200 mg abrocitinib commercial tablet. Part B of the study included administration of treatments D - I, famotidine 40 mg tablet + abrocitinib 200 mg oral suspension formulation X (X=1-6), and treatments B, J - N, abrocitinib 200 mg oral suspension formulation X (X=1-6) only. All were under fasted state on Day 1 of each period.	Treatment C-> B-> A-> J-> K-> L-> M-> N-> B Part A of the study included administration of treatments A - C. A=a single dose of abrocitinib 200 mg commercial tablet; B=a single dose of abrocitinib 200 mg oral suspension formulation 1, C=famotidine (40 mg) administered 120 minutes before a single dose of 200 mg abrocitinib commercial tablet. Part B of the study included administration of treatments D - I, famotidine 40 mg tablet + abrocitinib 200 mg oral suspension formulation X (X=1-6), and treatments B, J - N, abrocitinib 200 mg oral suspension formulation X (X=1-6) only. All were under fasted state on Day 1 of each period.
Overall Study Withdrawal by Subject	0	0	0	1	0	0

Baseline Characteristics

A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Treatment A-> B-> C-> D-> E-> F-> G-> H-> I n=3 Participants Part A of the study included administration of treatments A - C. A=a single dose of abrocitinib 200 mg commercial tablet; B=a single dose of abrocitinib 200 mg oral suspension formulation 1, C=famotidine (40 mg) administered 120 minutes before a single dose of 200 mg abrocitinib commercial tablet. Part B of the study included administration of treatments D - I, famotidine 40 mg tablet + abrocitinib 200 mg oral suspension formulation X (X=1-6), and treatments B, J - N, abrocitinib 200 mg oral suspension formulation X (X=1-6) only. All were under fasted state on Day 1 of each period.	Treatment A-> C-> B-> L-> M-> N-> B-> J-> K n=3 Participants Part A of the study included administration of treatments A - C. A=a single dose of abrocitinib 200 mg commercial tablet; B=a single dose of abrocitinib 200 mg oral suspension formulation 1, C=famotidine (40 mg) administered 120 minutes before a single dose of 200 mg abrocitinib commercial tablet. Part B of the study included administration of treatments D - I, famotidine 40 mg tablet + abrocitinib 200 mg oral suspension formulation X (X=1-6), and treatments B, J - N, abrocitinib 200 mg oral suspension formulation X (X=1-6) only. All were under fasted state on Day 1 of each period.	Treatment B-> A-> C-> K-> L-> M-> N-> B-> J n=3 Participants Part A of the study included administration of treatments A - C. A=a single dose of abrocitinib 200 mg commercial tablet; B=a single dose of abrocitinib 200 mg oral suspension formulation 1, C=famotidine (40 mg) administered 120 minutes before a single dose of 200 mg abrocitinib commercial tablet. Part B of the study included administration of treatments D - I, famotidine 40 mg tablet + abrocitinib 200 mg oral suspension formulation X (X=1-6), and treatments B, J - N, abrocitinib 200 mg oral suspension formulation X (X=1-6) only. All were under fasted state on Day 1 of each period.	Treatment B-> C-> A-> I-> D-> E-> F-> G-> H n=4 Participants Part A of the study included administration of treatments A - C. A=a single dose of abrocitinib 200 mg commercial tablet; B=a single dose of abrocitinib 200 mg oral suspension formulation 1, C=famotidine (40 mg) administered 120 minutes before a single dose of 200 mg abrocitinib commercial tablet. Part B of the study included administration of treatments D - I, famotidine 40 mg tablet + abrocitinib 200 mg oral suspension formulation X (X=1-6), and treatments B, J - N, abrocitinib 200 mg oral suspension formulation X (X=1-6) only. All were under fasted state on Day 1 of each period.	Treatment C-> A-> B-> H-> I-> D-> E-> F-> G n=3 Participants Part A of the study included administration of treatments A - C. A=a single dose of abrocitinib 200 mg commercial tablet; B=a single dose of abrocitinib 200 mg oral suspension formulation 1, C=famotidine (40 mg) administered 120 minutes before a single dose of 200 mg abrocitinib commercial tablet. Part B of the study included administration of treatments D - I, famotidine 40 mg tablet + abrocitinib 200 mg oral suspension formulation X (X=1-6), and treatments B, J - N, abrocitinib 200 mg oral suspension formulation X (X=1-6) only. All were under fasted state on Day 1 of each period.	Treatment C-> B-> A-> J-> K-> L-> M-> N-> B n=3 Participants Part A of the study included administration of treatments A - C. A=a single dose of abrocitinib 200 mg commercial tablet; B=a single dose of abrocitinib 200 mg oral suspension formulation 1, C=famotidine (40 mg) administered 120 minutes before a single dose of 200 mg abrocitinib commercial tablet. Part B of the study included administration of treatments D - I, famotidine 40 mg tablet + abrocitinib 200 mg oral suspension formulation X (X=1-6), and treatments B, J - N, abrocitinib 200 mg oral suspension formulation X (X=1-6) only. All were under fasted state on Day 1 of each period.	Total n=19 Participants Total of all reporting groups
Age, Continuous	34.3 Years STANDARD_DEVIATION 18.01 • n=5 Participants	34.3 Years STANDARD_DEVIATION 7.51 • n=7 Participants	42.3 Years STANDARD_DEVIATION 7.02 • n=5 Participants	42.0 Years STANDARD_DEVIATION 6.32 • n=4 Participants	34.7 Years STANDARD_DEVIATION 5.86 • n=21 Participants	43.3 Years STANDARD_DEVIATION 8.50 • n=10 Participants	38.7 Years STANDARD_DEVIATION 9.14 • n=115 Participants
Sex: Female, Male Female	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	2 Participants n=4 Participants	0 Participants n=21 Participants	2 Participants n=10 Participants	5 Participants n=115 Participants
Sex: Female, Male Male	3 Participants n=5 Participants	3 Participants n=7 Participants	2 Participants n=5 Participants	2 Participants n=4 Participants	3 Participants n=21 Participants	1 Participants n=10 Participants	14 Participants n=115 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants n=5 Participants	3 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=10 Participants	6 Participants n=115 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	2 Participants n=5 Participants	0 Participants n=7 Participants	3 Participants n=5 Participants	4 Participants n=4 Participants	2 Participants n=21 Participants	2 Participants n=10 Participants	13 Participants n=115 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	1 Participants n=115 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	1 Participants n=115 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants
Race (NIH/OMB) Black or African American	1 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants	2 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=10 Participants	8 Participants n=115 Participants
Race (NIH/OMB) White	2 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	2 Participants n=4 Participants	2 Participants n=21 Participants	2 Participants n=10 Participants	9 Participants n=115 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants

PRIMARY outcome

Timeframe: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.

Population: The analysis population refers to all participants dosed who had at least 1 of the PK parameters of primary interest in at least 1 treatment period.

Area under the plasma concentration time profile from time 0 extrapolated to infinity (AUCinf) was measured. The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.

Outcome measures

Outcome measures
Measure	Abrocitinib 200 mg Oral Suspension Formulation 4 Participants were given abrocitinib 200 mg oral suspension formulation 4.	Abrocitinib 200 mg Oral Suspension Formulation 5 Participants were given abrocitinib 200 mg oral suspension formulation 5.	Abrocitinib 200 mg Oral Suspension Formulation 6 Participants were given abrocitinib 200 mg oral suspension formulation 6.	Abrocitinib 200 mg Oral Suspension Formulation 1 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 1.	Abrocitinib 200 mg Oral Suspension Formulation 2 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 2.	Abrocitinib 200 mg Oral Suspension Formulation 3 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 3.
AUCinf of Abrocitinib Following the Administration of Abrocitinib Commercial Tablet, Abrocitinib Oral Suspension Formulation 1 or Famotidine Plus Abrocitinib Commerical Tablet	—	—	—	4623 nanogramhour per milliliter (nghr/mL) Geometric Coefficient of Variation 66	4601 nanogramhour per milliliter (nghr/mL) Geometric Coefficient of Variation 54	3096 nanogramhour per milliliter (nghr/mL) Geometric Coefficient of Variation 61

PRIMARY outcome

Timeframe: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.

Population: The analysis population refers to all participants dosed who had at least 1 of the PK parameters of primary interest in at least 1 treatment period.

Maximum observed plasma concentration (Cmax) was measured. The adjusted mean differences and 90% CIs for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.

Outcome measures

Outcome measures
Measure	Abrocitinib 200 mg Oral Suspension Formulation 4 Participants were given abrocitinib 200 mg oral suspension formulation 4.	Abrocitinib 200 mg Oral Suspension Formulation 5 Participants were given abrocitinib 200 mg oral suspension formulation 5.	Abrocitinib 200 mg Oral Suspension Formulation 6 Participants were given abrocitinib 200 mg oral suspension formulation 6.	Abrocitinib 200 mg Oral Suspension Formulation 1 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 1.	Abrocitinib 200 mg Oral Suspension Formulation 2 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 2.	Abrocitinib 200 mg Oral Suspension Formulation 3 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 3.
Cmax of Abrocitinib Following the Administration of Abrocitinib Commercial Tablet, Abrocitinib Oral Suspension Formulation 1 or Famotidine Plus Abrocitinib Commerical Tablet	—	—	—	1264 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 67	1218 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 56	189.1 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 77

PRIMARY outcome

Timeframe: 0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.

Population: All participants who had tasted the abrocitinib suspension formulations and made scores on the taste questionnaires were included in this analysis.

For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.

Outcome measures

Outcome measures
Measure	Abrocitinib 200 mg Oral Suspension Formulation 4 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 4.	Abrocitinib 200 mg Oral Suspension Formulation 5 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 5.	Abrocitinib 200 mg Oral Suspension Formulation 6 n=19 Participants Participants were given abrocitinib 200 mg oral suspension formulation 6.	Abrocitinib 200 mg Oral Suspension Formulation 1 n=19 Participants Participants were given abrocitinib 200 mg oral suspension formulation 1.	Abrocitinib 200 mg Oral Suspension Formulation 2 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 2.	Abrocitinib 200 mg Oral Suspension Formulation 3 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 3.
Assessment of Overall Liking After Administering Each Abrocitinib Oral Suspension Formulation (Formulation [F]1-F6) in Part B 5 min	40.32 Units on a scale Standard Deviation 32.691	71.87 Units on a scale Standard Deviation 24.190	67.34 Units on a scale Standard Deviation 27.632	40.21 Units on a scale Standard Deviation 35.480	69.59 Units on a scale Standard Deviation 25.882	42.83 Units on a scale Standard Deviation 34.549
Assessment of Overall Liking After Administering Each Abrocitinib Oral Suspension Formulation (Formulation [F]1-F6) in Part B 20 min	31.97 Units on a scale Standard Deviation 29.563	61.68 Units on a scale Standard Deviation 28.681	57.95 Units on a scale Standard Deviation 28.483	35.55 Units on a scale Standard Deviation 33.379	64.48 Units on a scale Standard Deviation 27.644	37.56 Units on a scale Standard Deviation 29.758
Assessment of Overall Liking After Administering Each Abrocitinib Oral Suspension Formulation (Formulation [F]1-F6) in Part B 0 Hours	42.19 Units on a scale Standard Deviation 34.366	71.08 Units on a scale Standard Deviation 27.491	69.29 Units on a scale Standard Deviation 27.565	42.32 Units on a scale Standard Deviation 35.117	72.10 Units on a scale Standard Deviation 24.243	44.95 Units on a scale Standard Deviation 34.422
Assessment of Overall Liking After Administering Each Abrocitinib Oral Suspension Formulation (Formulation [F]1-F6) in Part B 10 min	33.90 Units on a scale Standard Deviation 29.544	67.78 Units on a scale Standard Deviation 24.919	62.89 Units on a scale Standard Deviation 30.153	37.78 Units on a scale Standard Deviation 34.025	65.65 Units on a scale Standard Deviation 26.857	38.86 Units on a scale Standard Deviation 30.808

PRIMARY outcome

Timeframe: 0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.

Population: All participants who had tasted the abrocitinib suspension formulations and made scores on the taste questionnaires were included in this analysis.

For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.

Outcome measures

Outcome measures
Measure	Abrocitinib 200 mg Oral Suspension Formulation 4 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 4.	Abrocitinib 200 mg Oral Suspension Formulation 5 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 5.	Abrocitinib 200 mg Oral Suspension Formulation 6 n=19 Participants Participants were given abrocitinib 200 mg oral suspension formulation 6.	Abrocitinib 200 mg Oral Suspension Formulation 1 n=19 Participants Participants were given abrocitinib 200 mg oral suspension formulation 1.	Abrocitinib 200 mg Oral Suspension Formulation 2 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 2.	Abrocitinib 200 mg Oral Suspension Formulation 3 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 3.
Assessment of Mouth Feel After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 5 min	38.67 Units on a scale Standard Deviation 27.688	61.21 Units on a scale Standard Deviation 25.335	60.48 Units on a scale Standard Deviation 30.987	37.26 Units on a scale Standard Deviation 27.903	54.22 Units on a scale Standard Deviation 26.738	37.81 Units on a scale Standard Deviation 33.045
Assessment of Mouth Feel After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 10 min	31.90 Units on a scale Standard Deviation 24.808	55.33 Units on a scale Standard Deviation 27.451	52.36 Units on a scale Standard Deviation 31.626	35.61 Units on a scale Standard Deviation 29.456	50.57 Units on a scale Standard Deviation 26.578	35.18 Units on a scale Standard Deviation 33.222
Assessment of Mouth Feel After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 20 min	26.89 Units on a scale Standard Deviation 23.277	49.27 Units on a scale Standard Deviation 29.356	44.33 Units on a scale Standard Deviation 32.906	34.95 Units on a scale Standard Deviation 30.347	42.22 Units on a scale Standard Deviation 30.676	34.83 Units on a scale Standard Deviation 33.221
Assessment of Mouth Feel After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 0 Hours	42.10 Units on a scale Standard Deviation 30.178	63.59 Units on a scale Standard Deviation 25.544	61.59 Units on a scale Standard Deviation 31.543	40.12 Units on a scale Standard Deviation 28.336	61.59 Units on a scale Standard Deviation 26.218	40.79 Units on a scale Standard Deviation 33.908

PRIMARY outcome

Timeframe: 0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.

Population: All participants who had tasted the abrocitinib suspension formulations and made scores on the taste questionnaires were included in this analysis.

For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.

Outcome measures

Outcome measures
Measure	Abrocitinib 200 mg Oral Suspension Formulation 4 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 4.	Abrocitinib 200 mg Oral Suspension Formulation 5 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 5.	Abrocitinib 200 mg Oral Suspension Formulation 6 n=19 Participants Participants were given abrocitinib 200 mg oral suspension formulation 6.	Abrocitinib 200 mg Oral Suspension Formulation 1 n=19 Participants Participants were given abrocitinib 200 mg oral suspension formulation 1.	Abrocitinib 200 mg Oral Suspension Formulation 2 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 2.	Abrocitinib 200 mg Oral Suspension Formulation 3 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 3.
Assessment of Bitterness After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 0 Hours	28.63 Units on a scale Standard Deviation 21.634	70.76 Units on a scale Standard Deviation 27.869	63.28 Units on a scale Standard Deviation 23.400	39.25 Units on a scale Standard Deviation 30.773	64.25 Units on a scale Standard Deviation 27.312	32.06 Units on a scale Standard Deviation 27.383
Assessment of Bitterness After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 5 min	25.21 Units on a scale Standard Deviation 19.685	63.62 Units on a scale Standard Deviation 26.141	57.77 Units on a scale Standard Deviation 28.066	36.54 Units on a scale Standard Deviation 32.008	53.30 Units on a scale Standard Deviation 30.392	31.14 Units on a scale Standard Deviation 27.875
Assessment of Bitterness After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 10 min	20.95 Units on a scale Standard Deviation 19.000	53.65 Units on a scale Standard Deviation 25.657	49.41 Units on a scale Standard Deviation 26.827	33.80 Units on a scale Standard Deviation 31.609	47.72 Units on a scale Standard Deviation 31.067	27.27 Units on a scale Standard Deviation 25.124
Assessment of Bitterness After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 20 min	18.19 Units on a scale Standard Deviation 19.554	45.56 Units on a scale Standard Deviation 30.635	42.37 Units on a scale Standard Deviation 27.755	30.83 Units on a scale Standard Deviation 31.598	39.24 Units on a scale Standard Deviation 31.325	24.92 Units on a scale Standard Deviation 23.048

PRIMARY outcome

Timeframe: 0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.

Population: All participants who had tasted the abrocitinib suspension formulations and made scores on the taste questionnaires were included in this analysis.

For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.

Outcome measures

Outcome measures
Measure	Abrocitinib 200 mg Oral Suspension Formulation 4 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 4.	Abrocitinib 200 mg Oral Suspension Formulation 5 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 5.	Abrocitinib 200 mg Oral Suspension Formulation 6 n=19 Participants Participants were given abrocitinib 200 mg oral suspension formulation 6.	Abrocitinib 200 mg Oral Suspension Formulation 1 n=19 Participants Participants were given abrocitinib 200 mg oral suspension formulation 1.	Abrocitinib 200 mg Oral Suspension Formulation 2 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 2.	Abrocitinib 200 mg Oral Suspension Formulation 3 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 3.
Assessment of Tongue/Mouth Burn After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 0 Hours	26.89 Units on a scale Standard Deviation 25.884	35.75 Units on a scale Standard Deviation 30.848	41.05 Units on a scale Standard Deviation 32.462	28.90 Units on a scale Standard Deviation 26.489	41.87 Units on a scale Standard Deviation 30.238	25.87 Units on a scale Standard Deviation 23.920
Assessment of Tongue/Mouth Burn After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 5 min	22.67 Units on a scale Standard Deviation 24.999	28.76 Units on a scale Standard Deviation 25.809	37.89 Units on a scale Standard Deviation 33.134	24.48 Units on a scale Standard Deviation 25.226	35.40 Units on a scale Standard Deviation 28.451	22.86 Units on a scale Standard Deviation 22.477
Assessment of Tongue/Mouth Burn After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 10 min	18.29 Units on a scale Standard Deviation 22.999	22.82 Units on a scale Standard Deviation 25.042	36.99 Units on a scale Standard Deviation 32.737	23.73 Units on a scale Standard Deviation 26.631	31.24 Units on a scale Standard Deviation 26.305	18.29 Units on a scale Standard Deviation 20.001
Assessment of Tongue/Mouth Burn After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 20 min	16.51 Units on a scale Standard Deviation 22.374	17.68 Units on a scale Standard Deviation 21.927	33.68 Units on a scale Standard Deviation 32.903	21.65 Units on a scale Standard Deviation 28.937	23.97 Units on a scale Standard Deviation 26.386	15.40 Units on a scale Standard Deviation 20.156

PRIMARY outcome

Timeframe: 0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.

Population: All participants who had tasted the abrocitinib suspension formulations and made scores on the taste questionnaires were included in this analysis.

For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.

Outcome measures

Outcome measures
Measure	Abrocitinib 200 mg Oral Suspension Formulation 4 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 4.	Abrocitinib 200 mg Oral Suspension Formulation 5 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 5.	Abrocitinib 200 mg Oral Suspension Formulation 6 n=19 Participants Participants were given abrocitinib 200 mg oral suspension formulation 6.	Abrocitinib 200 mg Oral Suspension Formulation 1 n=19 Participants Participants were given abrocitinib 200 mg oral suspension formulation 1.	Abrocitinib 200 mg Oral Suspension Formulation 2 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 2.	Abrocitinib 200 mg Oral Suspension Formulation 3 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 3.
Assessment of Salty Taste After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 0 Hours	21.84 Units on a scale Standard Deviation 21.319	39.24 Units on a scale Standard Deviation 30.962	34.98 Units on a scale Standard Deviation 31.103	19.73 Units on a scale Standard Deviation 26.872	39.52 Units on a scale Standard Deviation 31.190	19.84 Units on a scale Standard Deviation 21.560
Assessment of Salty Taste After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 5 min	19.49 Units on a scale Standard Deviation 22.504	33.43 Units on a scale Standard Deviation 24.688	30.92 Units on a scale Standard Deviation 30.413	19.34 Units on a scale Standard Deviation 27.435	35.56 Units on a scale Standard Deviation 28.372	13.78 Units on a scale Standard Deviation 17.276
Assessment of Salty Taste After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 10 min	15.94 Units on a scale Standard Deviation 21.414	25.33 Units on a scale Standard Deviation 22.853	31.85 Units on a scale Standard Deviation 33.229	19.43 Units on a scale Standard Deviation 27.776	29.49 Units on a scale Standard Deviation 26.602	12.29 Units on a scale Standard Deviation 17.121
Assessment of Salty Taste After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 20 min	15.68 Units on a scale Standard Deviation 21.290	20.89 Units on a scale Standard Deviation 19.444	28.60 Units on a scale Standard Deviation 28.337	19.61 Units on a scale Standard Deviation 27.872	25.62 Units on a scale Standard Deviation 26.613	12.35 Units on a scale Standard Deviation 17.234

PRIMARY outcome

Timeframe: 0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.

Population: All participants who had tasted the abrocitinib suspension formulations and made scores on the taste questionnaires were included in this analysis.

For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.

Outcome measures

Outcome measures
Measure	Abrocitinib 200 mg Oral Suspension Formulation 4 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 4.	Abrocitinib 200 mg Oral Suspension Formulation 5 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 5.	Abrocitinib 200 mg Oral Suspension Formulation 6 n=19 Participants Participants were given abrocitinib 200 mg oral suspension formulation 6.	Abrocitinib 200 mg Oral Suspension Formulation 1 n=19 Participants Participants were given abrocitinib 200 mg oral suspension formulation 1.	Abrocitinib 200 mg Oral Suspension Formulation 2 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 2.	Abrocitinib 200 mg Oral Suspension Formulation 3 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 3.
Assessment of Sour Taste After Administering Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 0 Hours	25.65 Units on a scale Standard Deviation 22.452	48.35 Units on a scale Standard Deviation 34.210	47.37 Units on a scale Standard Deviation 33.103	25.44 Units on a scale Standard Deviation 26.343	52.54 Units on a scale Standard Deviation 27.703	24.86 Units on a scale Standard Deviation 24.663
Assessment of Sour Taste After Administering Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 5 min	21.71 Units on a scale Standard Deviation 22.198	41.02 Units on a scale Standard Deviation 31.652	39.73 Units on a scale Standard Deviation 32.655	24.54 Units on a scale Standard Deviation 26.919	46.32 Units on a scale Standard Deviation 28.172	21.75 Units on a scale Standard Deviation 23.849
Assessment of Sour Taste After Administering Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 20 min	18.16 Units on a scale Standard Deviation 20.241	28.98 Units on a scale Standard Deviation 31.338	34.31 Units on a scale Standard Deviation 31.151	21.68 Units on a scale Standard Deviation 27.373	37.05 Units on a scale Standard Deviation 30.426	16.95 Units on a scale Standard Deviation 21.472
Assessment of Sour Taste After Administering Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 10 min	19.18 Units on a scale Standard Deviation 20.652	33.30 Units on a scale Standard Deviation 31.797	36.33 Units on a scale Standard Deviation 32.522	23.16 Units on a scale Standard Deviation 27.074	42.44 Units on a scale Standard Deviation 29.892	18.70 Units on a scale Standard Deviation 21.879

PRIMARY outcome

Timeframe: 0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.

Population: All participants who had tasted the abrocitinib suspension formulations and made scores on the taste questionnaires were included in this analysis.

For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.

Outcome measures

Outcome measures
Measure	Abrocitinib 200 mg Oral Suspension Formulation 4 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 4.	Abrocitinib 200 mg Oral Suspension Formulation 5 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 5.	Abrocitinib 200 mg Oral Suspension Formulation 6 n=19 Participants Participants were given abrocitinib 200 mg oral suspension formulation 6.	Abrocitinib 200 mg Oral Suspension Formulation 1 n=19 Participants Participants were given abrocitinib 200 mg oral suspension formulation 1.	Abrocitinib 200 mg Oral Suspension Formulation 2 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 2.	Abrocitinib 200 mg Oral Suspension Formulation 3 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 3.
Assessment of Sweet Taste After Administering Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 0 Hours	27.90 Units on a scale Standard Deviation 24.626	78.48 Units on a scale Standard Deviation 28.017	74.53 Units on a scale Standard Deviation 29.874	31.16 Units on a scale Standard Deviation 26.157	82.16 Units on a scale Standard Deviation 19.816	30.16 Units on a scale Standard Deviation 29.536
Assessment of Sweet Taste After Administering Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 5 min	31.56 Units on a scale Standard Deviation 29.205	76.60 Units on a scale Standard Deviation 28.824	72.84 Units on a scale Standard Deviation 29.862	38.02 Units on a scale Standard Deviation 30.485	78.32 Units on a scale Standard Deviation 23.269	33.14 Units on a scale Standard Deviation 28.948
Assessment of Sweet Taste After Administering Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 20 min	33.33 Units on a scale Standard Deviation 31.472	73.46 Units on a scale Standard Deviation 31.151	62.50 Units on a scale Standard Deviation 33.720	44.54 Units on a scale Standard Deviation 34.296	75.18 Units on a scale Standard Deviation 26.743	35.46 Units on a scale Standard Deviation 29.622
Assessment of Sweet Taste After Administering Abrocitinib Oral Suspension Formulation (F1-F6) in Part B 10 min	32.38 Units on a scale Standard Deviation 32.348	74.86 Units on a scale Standard Deviation 29.812	64.81 Units on a scale Standard Deviation 33.275	40.42 Units on a scale Standard Deviation 32.265	78.35 Units on a scale Standard Deviation 23.383	33.52 Units on a scale Standard Deviation 29.713

SECONDARY outcome

Timeframe: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.

Population: The analysis population refers to all participants dosed who had at least 1 of the PK parameters of secondary interest in at least 1 treatment period.

Area under the plasma concentration time profile from time 0 extrapolated to infinity.

Outcome measures

Outcome measures
Measure	Abrocitinib 200 mg Oral Suspension Formulation 4 Participants were given abrocitinib 200 mg oral suspension formulation 4.	Abrocitinib 200 mg Oral Suspension Formulation 5 Participants were given abrocitinib 200 mg oral suspension formulation 5.	Abrocitinib 200 mg Oral Suspension Formulation 6 Participants were given abrocitinib 200 mg oral suspension formulation 6.	Abrocitinib 200 mg Oral Suspension Formulation 1 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 1.	Abrocitinib 200 mg Oral Suspension Formulation 2 n=13 Participants Participants were given abrocitinib 200 mg oral suspension formulation 2.	Abrocitinib 200 mg Oral Suspension Formulation 3 Participants were given abrocitinib 200 mg oral suspension formulation 3.
AUCinf of Abrocitinib Metabolite (PF-06471658/M1) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A	—	—	—	1048 ng*hr/mL Geometric Coefficient of Variation 34	903.2 ng*hr/mL Geometric Coefficient of Variation 32	—

SECONDARY outcome

Timeframe: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.

Population: The analysis population refers to all participants dosed who had at least 1 of the PK parameters of secondary interest in at least 1 treatment period.

Area under the plasma concentration time profile from time 0 extrapolated to infinity.

Outcome measures

Outcome measures
Measure	Abrocitinib 200 mg Oral Suspension Formulation 4 Participants were given abrocitinib 200 mg oral suspension formulation 4.	Abrocitinib 200 mg Oral Suspension Formulation 5 Participants were given abrocitinib 200 mg oral suspension formulation 5.	Abrocitinib 200 mg Oral Suspension Formulation 6 Participants were given abrocitinib 200 mg oral suspension formulation 6.	Abrocitinib 200 mg Oral Suspension Formulation 1 n=17 Participants Participants were given abrocitinib 200 mg oral suspension formulation 1.	Abrocitinib 200 mg Oral Suspension Formulation 2 n=7 Participants Participants were given abrocitinib 200 mg oral suspension formulation 2.	Abrocitinib 200 mg Oral Suspension Formulation 3 Participants were given abrocitinib 200 mg oral suspension formulation 3.
AUCinf of Abrocitinib Metabolite (PF-07055087/M2) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A	—	—	—	1369 ng*hr/mL Geometric Coefficient of Variation 22	1108 ng*hr/mL Geometric Coefficient of Variation 15	—

SECONDARY outcome

Timeframe: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.

Population: The analysis population refers to all participants dosed who had at least 1 of the PK parameters of secondary interest in at least 1 treatment period.

Area under the plasma concentration time profile from time 0 extrapolated to infinity.

Outcome measures

Outcome measures
Measure	Abrocitinib 200 mg Oral Suspension Formulation 4 Participants were given abrocitinib 200 mg oral suspension formulation 4.	Abrocitinib 200 mg Oral Suspension Formulation 5 Participants were given abrocitinib 200 mg oral suspension formulation 5.	Abrocitinib 200 mg Oral Suspension Formulation 6 Participants were given abrocitinib 200 mg oral suspension formulation 6.	Abrocitinib 200 mg Oral Suspension Formulation 1 n=15 Participants Participants were given abrocitinib 200 mg oral suspension formulation 1.	Abrocitinib 200 mg Oral Suspension Formulation 2 n=13 Participants Participants were given abrocitinib 200 mg oral suspension formulation 2.	Abrocitinib 200 mg Oral Suspension Formulation 3 Participants were given abrocitinib 200 mg oral suspension formulation 3.
AUCinf of Abrocitinib Metabolite (PF-07054874/M4) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A	—	—	—	2139 ng*hr/mL Geometric Coefficient of Variation 34	1705 ng*hr/mL Geometric Coefficient of Variation 33	—

SECONDARY outcome

Timeframe: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.

Population: The analysis population refers to all participants dosed who had at least 1 of the PK parameters of secondary interest in at least 1 treatment period.

Maximum observed plasma concentration.

Outcome measures

Outcome measures
Measure	Abrocitinib 200 mg Oral Suspension Formulation 4 Participants were given abrocitinib 200 mg oral suspension formulation 4.	Abrocitinib 200 mg Oral Suspension Formulation 5 Participants were given abrocitinib 200 mg oral suspension formulation 5.	Abrocitinib 200 mg Oral Suspension Formulation 6 Participants were given abrocitinib 200 mg oral suspension formulation 6.	Abrocitinib 200 mg Oral Suspension Formulation 1 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 1.	Abrocitinib 200 mg Oral Suspension Formulation 2 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 2.	Abrocitinib 200 mg Oral Suspension Formulation 3 Participants were given abrocitinib 200 mg oral suspension formulation 3.
Cmax of Abrocitinib Metabolite (PF-06471658/M1) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A	—	—	—	216.8 ng/mL Geometric Coefficient of Variation 82	57.38 ng/mL Geometric Coefficient of Variation 55	—

SECONDARY outcome

Timeframe: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.

Population: The analysis population refers to all participants dosed who had at least 1 of the PK parameters of secondary interest in at least 1 treatment period.

Maximum observed plasma concentration.

Outcome measures

Outcome measures
Measure	Abrocitinib 200 mg Oral Suspension Formulation 4 Participants were given abrocitinib 200 mg oral suspension formulation 4.	Abrocitinib 200 mg Oral Suspension Formulation 5 Participants were given abrocitinib 200 mg oral suspension formulation 5.	Abrocitinib 200 mg Oral Suspension Formulation 6 Participants were given abrocitinib 200 mg oral suspension formulation 6.	Abrocitinib 200 mg Oral Suspension Formulation 1 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 1.	Abrocitinib 200 mg Oral Suspension Formulation 2 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 2.	Abrocitinib 200 mg Oral Suspension Formulation 3 Participants were given abrocitinib 200 mg oral suspension formulation 3.
Cmax of Abrocitinib Metabolite (PF-07055087/M2) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A	—	—	—	214.3 ng/mL Geometric Coefficient of Variation 58	56.42 ng/mL Geometric Coefficient of Variation 42	—

SECONDARY outcome

Timeframe: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.

Population: The analysis population refers to all participants dosed who had at least 1 of the PK parameters of secondary interest in at least 1 treatment period.

Maximum observed plasma concentration.

Outcome measures

Outcome measures
Measure	Abrocitinib 200 mg Oral Suspension Formulation 4 Participants were given abrocitinib 200 mg oral suspension formulation 4.	Abrocitinib 200 mg Oral Suspension Formulation 5 Participants were given abrocitinib 200 mg oral suspension formulation 5.	Abrocitinib 200 mg Oral Suspension Formulation 6 Participants were given abrocitinib 200 mg oral suspension formulation 6.	Abrocitinib 200 mg Oral Suspension Formulation 1 n=17 Participants Participants were given abrocitinib 200 mg oral suspension formulation 1.	Abrocitinib 200 mg Oral Suspension Formulation 2 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 2.	Abrocitinib 200 mg Oral Suspension Formulation 3 Participants were given abrocitinib 200 mg oral suspension formulation 3.
Cmax of Abrocitinib Metabolite (PF-07054874/M4) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A	—	—	—	400.5 ng/mL Geometric Coefficient of Variation 39	87.96 ng/mL Geometric Coefficient of Variation 47	—

SECONDARY outcome

Timeframe: Baseline up to follow-up (Day 36)

Population: All participants randomly assigned to study intervention and who take at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received.

Adverse events (AEs): any untoward medical occurrence in a clinical investigation participant administered a product, without regard to relatedness. Treatment-emergent AEs (TEAEs): AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Treatment-related TEAEs were any untoward medical occurrence attributed to study intervention. Relatedness to study intervention was determined by the investigator.

Outcome measures

Outcome measures
Measure	Abrocitinib 200 mg Oral Suspension Formulation 4 n=9 Participants Participants were given abrocitinib 200 mg oral suspension formulation 4.	Abrocitinib 200 mg Oral Suspension Formulation 5 n=10 Participants Participants were given abrocitinib 200 mg oral suspension formulation 5.	Abrocitinib 200 mg Oral Suspension Formulation 6 Participants were given abrocitinib 200 mg oral suspension formulation 6.	Abrocitinib 200 mg Oral Suspension Formulation 1 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 1.	Abrocitinib 200 mg Oral Suspension Formulation 2 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 2.	Abrocitinib 200 mg Oral Suspension Formulation 3 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 3.
Number of Participants With Treatment-Emergent Adverse Event All-causality AEs	5 Participants	2 Participants	—	6 Participants	8 Participants	6 Participants
Number of Participants With Treatment-Emergent Adverse Event Treatment-related AEs	4 Participants	0 Participants	—	3 Participants	5 Participants	0 Participants
Number of Participants With Treatment-Emergent Adverse Event SAEs	0 Participants	0 Participants	—	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Baseline up to follow-up (Day 36)

Population: All participants randomly assigned to study intervention and who take at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received.

Participants with laboratory abnormalities (without regard to baseline abnormality) were reported.

Outcome measures

Outcome measures
Measure	Abrocitinib 200 mg Oral Suspension Formulation 4 n=9 Participants Participants were given abrocitinib 200 mg oral suspension formulation 4.	Abrocitinib 200 mg Oral Suspension Formulation 5 n=10 Participants Participants were given abrocitinib 200 mg oral suspension formulation 5.	Abrocitinib 200 mg Oral Suspension Formulation 6 Participants were given abrocitinib 200 mg oral suspension formulation 6.	Abrocitinib 200 mg Oral Suspension Formulation 1 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 1.	Abrocitinib 200 mg Oral Suspension Formulation 2 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 2.	Abrocitinib 200 mg Oral Suspension Formulation 3 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 3.
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)	0 Participants	0 Participants	—	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Baseline up to follow-up (Day 36)

Population: All participants randomly assigned to study intervention and who take at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received.

Participants with clinically significant vital sign values were reported.

Outcome measures

Outcome measures
Measure	Abrocitinib 200 mg Oral Suspension Formulation 4 n=9 Participants Participants were given abrocitinib 200 mg oral suspension formulation 4.	Abrocitinib 200 mg Oral Suspension Formulation 5 n=10 Participants Participants were given abrocitinib 200 mg oral suspension formulation 5.	Abrocitinib 200 mg Oral Suspension Formulation 6 Participants were given abrocitinib 200 mg oral suspension formulation 6.	Abrocitinib 200 mg Oral Suspension Formulation 1 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 1.	Abrocitinib 200 mg Oral Suspension Formulation 2 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 2.	Abrocitinib 200 mg Oral Suspension Formulation 3 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 3.
Number of Participants With Clinically Significant Vital Sign Values	0 Participants	0 Participants	—	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Baseline up to follow-up (Day 36)

Population: All participants randomly assigned to study intervention and who take at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received.

Participants with clinically significant abnormal ECG values were reported.

Outcome measures

Outcome measures
Measure	Abrocitinib 200 mg Oral Suspension Formulation 4 n=9 Participants Participants were given abrocitinib 200 mg oral suspension formulation 4.	Abrocitinib 200 mg Oral Suspension Formulation 5 n=10 Participants Participants were given abrocitinib 200 mg oral suspension formulation 5.	Abrocitinib 200 mg Oral Suspension Formulation 6 Participants were given abrocitinib 200 mg oral suspension formulation 6.	Abrocitinib 200 mg Oral Suspension Formulation 1 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 1.	Abrocitinib 200 mg Oral Suspension Formulation 2 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 2.	Abrocitinib 200 mg Oral Suspension Formulation 3 n=18 Participants Participants were given abrocitinib 200 mg oral suspension formulation 3.
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Values	0 Participants	0 Participants	—	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Baseline up to follow-up (Day 36)

Population: All participants who received at least 1 dose of abrocitinib 200 mg alone or abrocitinib 200 mg plus famotidine 40 mg.

Number of participants who received abrocitinib 200 mg alone and who received abrocitinib 200 mg plus famotidine 40 mg and had nausea AEs were reported.

Outcome measures

Outcome measures
Measure	Abrocitinib 200 mg Oral Suspension Formulation 4 Participants were given abrocitinib 200 mg oral suspension formulation 4.	Abrocitinib 200 mg Oral Suspension Formulation 5 Participants were given abrocitinib 200 mg oral suspension formulation 5.	Abrocitinib 200 mg Oral Suspension Formulation 6 Participants were given abrocitinib 200 mg oral suspension formulation 6.	Abrocitinib 200 mg Oral Suspension Formulation 1 n=45 Participants Participants were given abrocitinib 200 mg oral suspension formulation 1.	Abrocitinib 200 mg Oral Suspension Formulation 2 n=28 Participants Participants were given abrocitinib 200 mg oral suspension formulation 2.	Abrocitinib 200 mg Oral Suspension Formulation 3 Participants were given abrocitinib 200 mg oral suspension formulation 3.
Number of Participants With Nausea AEs	—	—	—	12 Participants	0 Participants	—

Adverse Events

Abrocitinib 200 mg Commercial Tablet

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

Abrocitinib 200 mg Oral Suspension Formulation 1

Serious events: 0 serious events

Other events: 8 other events

Deaths: 0 deaths

Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

Aborcitinib 200 mg Oral Suspension Formulation 1-6

Serious events: 0 serious events

Other events: 5 other events

Deaths: 0 deaths

Famotidine 40 mg Tablet + Abrocitinib 200 mg Oral Suspension Formulation 1-6

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure	Abrocitinib 200 mg Commercial Tablet n=18 participants at risk In part A of the study, abrocitinib 200 mg commercial tablet was administered on Day 1 under fasted conditions.	Abrocitinib 200 mg Oral Suspension Formulation 1 n=18 participants at risk In part A of the study, abrocitinib 200 mg oral suspension formulation 1 was administered on Day 1 under fasted conditions.	Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet n=18 participants at risk In part A of the study, aamotidine 40 mg tablet + Abrocitinib 200 mg commercial tablet were administered on Day 1 under fasted conditions.	Aborcitinib 200 mg Oral Suspension Formulation 1-6 n=9 participants at risk In part B of the study, aborcitinib 200 mg oral suspension formulation 1-6 were administered on Day 1 od each period under fasting conditions.	Famotidine 40 mg Tablet + Abrocitinib 200 mg Oral Suspension Formulation 1-6 n=10 participants at risk In part B of the study, famotidine 40 mg tablet + abrocitinib 200 mg oral suspension formulation 1-6 were administered on Day 1 of each period under fasting conditions.
Gastrointestinal disorders Diarrhoea	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	5.6% 1/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/9 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/10 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.
Ear and labyrinth disorders Ear pain	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	5.6% 1/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/9 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/10 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.
Gastrointestinal disorders Dyspepsia	5.6% 1/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/9 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/10 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.
Gastrointestinal disorders Nausea	16.7% 3/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	27.8% 5/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	44.4% 4/9 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/10 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.
Gastrointestinal disorders Vomiting	5.6% 1/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/9 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/10 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.
General disorders Feeling abnormal	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	5.6% 1/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	11.1% 1/9 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/10 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.
General disorders Hunger	5.6% 1/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	22.2% 2/9 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/10 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.
General disorders Vessel puncture site haematoma	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	5.6% 1/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/9 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/10 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.
General disorders Vessel puncture site pain	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	5.6% 1/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	11.1% 1/9 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/10 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.
Injury, poisoning and procedural complications Incision site complication	11.1% 2/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	11.1% 2/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	22.2% 4/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/9 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/10 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.
Injury, poisoning and procedural complications Incision site haemorrhage	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	5.6% 1/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/9 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/10 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.
Nervous system disorders Headache	11.1% 2/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	16.7% 3/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	11.1% 1/9 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/10 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.
Nervous system disorders Presyncope	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	5.6% 1/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/9 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/10 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.
Skin and subcutaneous tissue disorders Pruritus	5.6% 1/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/9 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/10 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/9 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	10.0% 1/10 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.
Injury, poisoning and procedural complications Contusion	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/9 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	10.0% 1/10 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.
Nervous system disorders Tension headache	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/9 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	10.0% 1/10 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.
Skin and subcutaneous tissue disorders Acne	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/18 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	11.1% 1/9 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.	0.00% 0/10 • Baseline up to follow-up (Day 36) Occurrences of AEs in this study were reported according to the study interventions that participants received, according to the study safety objective. Abrocitinib 200 mg oral suspension formulations (with different flavors) were prepared with different levels of flavor and sweetener at study site, and any AEs occurrences for these study interventions were combined to ensure the presentation of safety profiles of Abrocitinib 200 mg oral suspension formulation.

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer Inc.

Phone: 1-800-718-1021

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place